Springworks Therapeutics Intrinsic Value Calculator – FDA Grants Deadline Extension for SpringWorks Therapeutics’ Nirogacestat Drug Application
June 18, 2023
☀️Trending News
SPRINGWORKS ($NASDAQ:SWTX): SpringWorks Therapeutics, a biopharmaceutical company focused on developing treatments for rare and complex diseases, recently received some good news from the US Food and Drug Administration (FDA). The FDA has granted an extension on the deadline for its nirogacestat drug application. Nirogacestat is a therapy being developed to treat Desmoid Tumors, a rare and aggressive type of soft tissue tumor. This extension grants SpringWorks more time to provide additional information for its drug application and is seen as a major step forward for the company. The extension also helps to bolster confidence in the drug’s potential approval, which could be a major milestone for SpringWorks and its shareholders.
It also signals that the FDA recognizes the importance of the drug to those who suffer from this rare disease. SpringWorks Therapeutics is committed to providing novel solutions to rare and complex diseases with limited or no treatments. As such, the success of this drug application could prove to be a breakthrough for many people suffering from Desmoid Tumors. This extended deadline marks a major milestone for SpringWorks and provides hope that the much-needed nirogacestat therapy will be approved soon.
Market Price
On Monday, the U.S. Food and Drug Administration (FDA) granted SPRINGWORKS THERAPEUTICS an extension to its drug application for Nirogacestat, an investigational drug for the treatment of aggressive tumors. In response to the news, SPRINGWORKS THERAPEUTICS stock opened at $26.8 and closed the day at $26.6, down by 2.6% from its previous closing price of 27.3. This decision by the FDA has given the company more time to submit additional information about its drug application in order to gain approval for Nirogacestat. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Springworks Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -289.04 | -130.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Springworks Therapeutics. More…
| Operations | Investing | Financing |
| -174.69 | -143.42 | 338.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Springworks Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 569.2 | 62.27 | 8.11 |
Key Ratios Snapshot
Some of the financial key ratios for Springworks Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -132.4% |
| FCF Margin | ROE | ROA |
| -93.8% | -34.8% | -32.6% |
Analysis – Springworks Therapeutics Intrinsic Value Calculator
At GoodWhale, we’ve recently conducted a fundamental analysis of SPRINGWORKS THERAPEUTICS and its stock. We calculate that the intrinsic value of SPRINGWORKS THERAPEUTICS share is around $45.9. This was determined through our proprietary Valuation Line. However, the current market price of SPRINGWORKS THERAPEUTICS stock is $26.6 – which is undervalued by 42.1%. This makes SPRINGWORKS THERAPEUTICS stock a potentially attractive investment option. More…
Peers
The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.
– Immunic Inc ($NASDAQ:IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.
Summary
SpringWorks Therapeutics is a biopharmaceutical company focused on developing treatments for rare and underserved diseases. For potential investors, this is a strong indication that the drug is promising and likely to receive approval. The company also has a pipeline of other drugs in development for other rare diseases. With the FDA’s positive response and the potential for other drugs to gain approval, SpringWorks Therapeutics could be a beneficial investment opportunity for those looking to capitalize on the rapidly growing biopharmaceutical industry.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
